Hematopoietic growth factors: Personalization of risks and benefits

Shannon Puhalla, Saveri Bhattacharya, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalMolecular Oncology
Volume6
Issue number2
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Granulocyte Colony-Stimulating Factor
Erythropoietin
Anemia
Intercellular Signaling Peptides and Proteins
Bone Marrow
Morbidity
Mortality
Neoplasms
Therapeutics

Keywords

  • Erythropoietin stimulating agents (ESAs)
  • Granulocyte colony stimulating factors (GCSF)
  • Pegfilgastrim

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Hematopoietic growth factors : Personalization of risks and benefits. / Puhalla, Shannon; Bhattacharya, Saveri; Davidson, Nancy E.

In: Molecular Oncology, Vol. 6, No. 2, 04.2012, p. 237-241.

Research output: Contribution to journalArticle

Puhalla, Shannon ; Bhattacharya, Saveri ; Davidson, Nancy E. / Hematopoietic growth factors : Personalization of risks and benefits. In: Molecular Oncology. 2012 ; Vol. 6, No. 2. pp. 237-241.
@article{2bc51187012d42738a47a36714893667,
title = "Hematopoietic growth factors: Personalization of risks and benefits",
abstract = "A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.",
keywords = "Erythropoietin stimulating agents (ESAs), Granulocyte colony stimulating factors (GCSF), Pegfilgastrim",
author = "Shannon Puhalla and Saveri Bhattacharya and Davidson, {Nancy E.}",
year = "2012",
month = "4",
doi = "10.1016/j.molonc.2012.03.001",
language = "English (US)",
volume = "6",
pages = "237--241",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Hematopoietic growth factors

T2 - Personalization of risks and benefits

AU - Puhalla, Shannon

AU - Bhattacharya, Saveri

AU - Davidson, Nancy E.

PY - 2012/4

Y1 - 2012/4

N2 - A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

AB - A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

KW - Erythropoietin stimulating agents (ESAs)

KW - Granulocyte colony stimulating factors (GCSF)

KW - Pegfilgastrim

UR - http://www.scopus.com/inward/record.url?scp=84860445233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860445233&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2012.03.001

DO - 10.1016/j.molonc.2012.03.001

M3 - Article

C2 - 22497867

AN - SCOPUS:84860445233

VL - 6

SP - 237

EP - 241

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 2

ER -